Navigation Links
Focused Radiation May Help Some With Lung Cancer
Date:11/4/2009

Study reports successes, especially for those with good lung function

WEDNESDAY, Nov. 4 (HealthDay News) -- Three-year survival was 100 percent for people with early-stage lung cancer and good lung function who were treated with radical stereotactic radiosurgery using CyberKnife, according to a new study funded by the product's maker.

Standard care for people with small lung tumors calls for surgical removal of the affected lobe, but some people cannot have surgery because of other medical conditions, such as heart disease or emphysema.

"Our goal has been to find a reasonable option for patients who don't want or can't tolerate surgery," the study's lead author, Dr. Brian T. Collins, a radiation oncologist at the Lombardi Comprehensive Cancer Center at Georgetown University Hospital, said in a news release from the university. "What we discovered is a very promising option that may be relevant for other stage 1 patients as well. More follow-up with these patients is planned to see how they progress five years after treatment."

Stereotactic radiosurgery, despite its name, is not surgery but rather a type of radiation therapy that focuses high-powered X-rays on abnormal tissue only, sparing nearby healthy tissue.

The study included 24 people with early-stage lung cancer. Three years after undergoing stereotactic radiosurgery, overall survival was 79 percent. Five deaths were attributed to progressive lung dysfunction. But among those with better lung function, survival was 100 percent, the researchers reported. The treatment was found to be well tolerated, with most people reporting only mild fatigue.

"What we also learned from this study is that patients with poorer lung functioning don't do nearly as well," Collins stated in the news release. The overall survival in this group of patients was only 30 percent, the researchers found.

"This information is important for the doctor and pati
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Philips Healthcare CEO Joins Focused Ultrasound Surgery Foundation Board of Directors
2. XLHealth Applauds Quality Focused Reforms in Senate Finance Committee Legislation
3. Focused Radiation Protects Tumor Patients Brain Function
4. President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development
5. Focused Learning Environment Guides Student Success
6. Founder of Curidium Launches Elixior, an Advisory Company Focused on the Development and Growth of Innovative Personalized Medicine Businesses
7. Health2 Resources Announces News Portal, E-News Brief Focused on Patient Centered Medical Home
8. Kaiser Permanente Debuts New Ads Focused on Technology and Innovation
9. FertilityTies, Social Network for the Fertility-Focused Unveils New Site Design, Unique Features to Help Patients Find Fertility Doctors & More
10. Focused Health Solutions Selects Cardiocom Telehealth Technology to Support Early Intervention
11. Health Integrated Hosts Industry Collaborative Focused on the Patient-Centered Medical Home (PCMH)
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Volcano Corporation Presentation At Canaccord Adams Conference To Be Webcast 13452 1Volcano Corporation Presentation At Canaccord Adams Conference To Be Webcast 13452 2More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 53936 1More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 53936 2More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 53936 3More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 53936 4More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 53936 5Sanofi Pasteur Submits Supplemental Application for A 28H1N1 29 Pandemic Vaccine to U S FDA 4835 1Sanofi Pasteur Submits Supplemental Application for A 28H1N1 29 Pandemic Vaccine to U S FDA 4835 2Sanofi Pasteur Submits Supplemental Application for A 28H1N1 29 Pandemic Vaccine to U S FDA 4835 3